Evista will be used more to reduce the risk of breast cancer

Evista will be used more to reduce the risk of breast cancer.

The FDA just approved this use for postmenopausal women with osteoporosis...or those at high risk for breast cancer.

Many already use Evista (raloxifene) as an alternative to tamoxifen to reduce breast cancer risk.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote